Literature DB >> 24168903

Rehabilitation with dental implants in microvascular iliac graft after solid ameloblastoma resection: a case report.

Rafael Netto1, Wladimir Cortezzi, Tomaz Nassif, Mônica Calasans-Maia, Rafael Seabra Louro.   

Abstract

PURPOSE: Ameloblastoma is a true odontogenic tumor that is most frequently found in clinical practice. Osseous resection with clear margins is the recommended treatment followed by bone reconstruction, such as a vascularized graft. The use of osseointegrated dental implants for rehabilitation is advisable, as it allows the recovery of the masticatory function.
MATERIALS AND METHODS: This case report includes 1 subject, a patient who presented with a large ameloblastoma treated by resection, a microvascular iliac graft, and dental implants.
RESULTS: After 6 months of regular control, the patient exhibited perfect healing of both the soft tissues and bone graft. At the time of this report, the patient had undergone 36 months of clinical and radiographic follow-up and had not exhibited any sign of osseous loss, implant mobility, or tumor recurrence.
CONCLUSIONS: The outcome of this case indicates that a microvascular graft and subsequent dental implantation is a good treatment plan that aids in a quick functional rehabilitation in ameloblastoma patients.

Entities:  

Mesh:

Year:  2013        PMID: 24168903     DOI: 10.1097/ID.0000000000000007

Source DB:  PubMed          Journal:  Implant Dent        ISSN: 1056-6163            Impact factor:   2.454


  2 in total

1.  Postsurgical Prosthetic Rehabilitation after Mandibular Ameloblastoma Resection: A 7-Year Follow-Up Case Report.

Authors:  C Moreno-Soriano; A Estrugo-Devesa; P Castañeda-Vega; E Jané-Salas; J López-López
Journal:  Case Rep Dent       Date:  2021-03-28

2.  Possibility of Using Flexible Dentures over Iliac Bone Graft in Adolescent Patients with Ameloblastoma: A 9-Month Follow-Up Clinical Report.

Authors:  Ammar Belal; Bassil Monther; Wael Alzarif
Journal:  Case Rep Dent       Date:  2021-11-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.